C12N 2710/10032
Use of virus as therapeutic agent, other than vaccine
Official title: Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
C12N2710/10032 (Use of virus as therapeutic agent, other than vaccine) appears on 78 US grants and 149 published applications in this corpus.
Search patents in C12N- Granted patents
- 78
- Published applications
- 149
- Assignees
- 67
- Inventors
- 196
- Latest grant
- 23 Jun 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2001 | 0 | 1 |
| 2002 | 0 | 2 |
| 2003 | 2 | 0 |
| 2004 | 0 | 1 |
| 2005 | 0 | 4 |
| 2006 | 0 | 2 |
| 2007 | 1 | 2 |
| 2008 | 0 | 5 |
| 2009 | 3 | 7 |
| 2010 | 2 | 2 |
| 2011 | 2 | 3 |
| 2012 | 1 | 4 |
| 2013 | 1 | 6 |
| 2014 | 1 | 0 |
| 2015 | 6 | 16 |
| 2016 | 3 | 15 |
| 2017 | 3 | 12 |
| 2018 | 9 | 3 |
| 2019 | 5 | 11 |
| 2020 | 8 | 5 |
| 2021 | 6 | 8 |
| 2022 | 4 | 9 |
| 2023 | 4 | 5 |
| 2024 | 5 | 10 |
| 2025 | 10 | 10 |
| 2026 | 2 | 6 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Selective stimulation of T cells in solid tumors using oncolytic viral delivery of orthogonal IL-223 Jun 2026US 12,661,401 B2The Regents of the University of California
- Oncolytic adenovirus compositions31 Mar 2026US 12,589,128 B2The Salk Institute for Biological Studies
- Activation of resident memory T cells for cancer immunotherapy23 Dec 2025US 12,502,406 B2Regents of the University of Minnesota
- Enhanced adoptive cell therapy23 Sep 2025US 12,421,502 B2Tilt Biotherapeutics Oy
- Composition comprising NC886 for improving oncolytic virus activity or production26 Aug 2025US 12,398,376 B2National Cancer Center
- Materials and methods for increasing immune responses within a mammal8 Oct 2026US 2026/0306668 A1Mayo Foundation for Medical Education and Research
- Dosing regime and formulations for type b adenoviruses30 Jul 2026US 2026/0216263 A1Akamis Bio Limited
- Activation of resident memory t cells for cancer immunotherapy28 May 2026US 2026/0144820 A1New York Society for the Relief of the Ruptured and Crippled, maintaining the Hospital for Special
- Oncolytic adenoviral vector and methods of use16 Apr 2026US 2026/0102445 A1Unleash Immuno Oncolytics, Inc.
- Enhanced adoptive cell therapy19 Mar 2026US 2026/0078349 A1
Most cited
By later US patents
- Viruses for the treatment of cellular proliferative disorders41US 6,649,157 B2Oncolytics Biotech Inc. · 2003
- Chimeric adenoviruses for use in cancer treatment33US 7,510,868 B22009
- Viruses for the treatment of cellular proliferative disorders27US 6,596,268 B1Oncolytics Biotech Inc. · 2003
- Viruses for the treatment of cellular proliferative disorders26US 7,252,817 B2Oncolytics Biotech Inc. · 2007
- Methods and compositions for attenuating exon skipping anti-viral transfer vector immune responses17US 10,046,064 B2Selecta Biosciences, Inc. · 2018